申请人:Ono Pharmaceutical Co., Ltd.
公开号:US05892099A1
公开(公告)日:1999-04-06
A 3,7-dithiaprostanoic acid derivative of the formula (I) ##STR1## (wherein R.sup.1 is OH, C1-4 alkoxy, NR.sup.6 R.sup.7 (wherein R.sup.6, R.sup.7 are H, C1-4);R.sup.2 is H, OH; R.sup.3 is (i)alkyl, alkenyl, alkynyl (ii) phenyl, cycloalkyl (iii) alkyl, alkenyl, alkynyl substituted by phenyl, cycloalkyl (when R.sup.2 is H, alkyl, alkenyl, alkynyl in (i) or (iii) may be substituted by OH) possesses a binding activity for PGE.sub.2 receptor (especially for EP4). Therefore they are useful for the treatment and/or prevention of immunologic diseases (autoimmune diseases, immunological deficiency diseases, organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardiac ischemia etc.
公式(I)的3,7-二硫代前列腺酸衍生物如下:##STR1##(其中R.sup.1为OH,C1-4烷氧基,NR.sup.6R.sup.7(其中R.sup.6,R.sup.7为H,C1-4); R.sup.2为H,OH; R.sup.3为(i)烷基,烯基,炔基(ii)苯基,环烷基(iii)烷基,烯基,炔基,被苯基,环烷基取代(当R.sup.2为H时,(i)或(iii)中的烷基,烯基,炔基可能被OH取代)。它们具有与PGE.sub.2受体(特别是EP4)的结合活性。因此,它们对于治疗和/或预防免疫性疾病(自身免疫性疾病,免疫缺陷病,器官移植等),哮喘,异常骨形成,神经元细胞死亡,肝损伤,肾炎,高血压,心肌缺血等是有用的。